Martin Schaefer, MD; Thomas Berg, MD; Susanne Sarkar; Konrad Neumann, PhD
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2214.
Schaefer M, Berg T, Sarkar S, Neumann K. Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression. Ann Intern Med. 2013;158:140. doi: 10.7326/0003-4819-158-2-201301150-00020
Download citation file:
Published: Ann Intern Med. 2013;158(2):140.
On the basis of Dr. Landman's comments, we noticed that our primary entry in the ClinicalTrials.gov database was not updated with details of the final protocol and, indeed, included a mistake: The HAM-D was listed as the instrument for the primary outcome measurement instead of the MADRS. This has been communicated to the ClinicalTrials.gov registry so that a correction can be posted. Nevertheless, we must emphasize that the MADRS and not the HAM-D was defined as the primary outcome before any patient was included in our final study protocol, which was approved by the responsible ethics committee of Charité Berlin and the local ethics committees of the participating centers.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only